- Home
- PRQR vs AVR Comparison
PRQR vs AVR Comparison
Compare PRQR & AVR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRQR
- AVR
- Stock Information
- Founded
- PRQR 2012
- AVR 1999
- Country
- PRQR Netherlands
- AVR Australia
- Employees
- PRQR N/A
- AVR N/A
- Industry
- PRQR Biotechnology: Pharmaceutical Preparations
- AVR
- Sector
- PRQR Health Care
- AVR
- Exchange
- PRQR Nasdaq
- AVR NYSE
- Market Cap
- PRQR 179.1M
- AVR 162.1M
- IPO Year
- PRQR 2014
- AVR 2024
- Fundamental
- Price
- PRQR $1.94
- AVR $4.87
- Analyst Decision
- PRQR Strong Buy
- AVR Strong Buy
- Analyst Count
- PRQR 7
- AVR 4
- Target Price
- PRQR $9.00
- AVR $16.50
- AVG Volume (30 Days)
- PRQR 302.0K
- AVR 172.4K
- Earning Date
- PRQR 08-07-2025
- AVR 05-13-2025
- Dividend Yield
- PRQR N/A
- AVR N/A
- EPS Growth
- PRQR N/A
- AVR N/A
- EPS
- PRQR N/A
- AVR N/A
- Revenue
- PRQR $21,212,711.00
- AVR $2,493,000.00
- Revenue This Year
- PRQR $2.87
- AVR $25.79
- Revenue Next Year
- PRQR N/A
- AVR $211.91
- P/E Ratio
- PRQR N/A
- AVR N/A
- Revenue Growth
- PRQR 85.91
- AVR N/A
- 52 Week Low
- PRQR $1.07
- AVR $2.34
- 52 Week High
- PRQR $4.62
- AVR $8.79
- Technical
- Relative Strength Index (RSI)
- PRQR 63.06
- AVR N/A
- Support Level
- PRQR $1.77
- AVR N/A
- Resistance Level
- PRQR $1.96
- AVR N/A
- Average True Range (ATR)
- PRQR 0.10
- AVR 0.00
- MACD
- PRQR 0.01
- AVR 0.00
- Stochastic Oscillator
- PRQR 80.78
- AVR 0.00
About PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics.
About AVR ANTERIS TECHNOLOGIES GLOBAL CORP
Anteris Technologies Global Corp. is a structural heart company committed to discovering, developing and commercializing medical devices designed to improve the quality of life for patients with aortic stenosis. Its product, the DurAVR THV system, represents a product opportunity in a new THV class of single-piece heart valves, for the treatment of aortic stenosis. Its DurAVR THV system consists of a single-piece, biomimetic valve made with its proprietary ADAPT tissue-enhancing technology and deployed with its ComASUR balloon-expandable delivery system. ADAPT is its proprietary anti-calcification tissue shaping technology that is designed to reengineer xenograft tissue into a pure, single-piece collagen bioscaffold.